The prototype AeroChamber2go* spacer device was preferred by patients compared to the A2A† spacer and provides a good option for patients currently using the Metered Dose Inhaler without a spacer while on-the-go.
A systematic review of nebulizer use highlighted a few different potential mechanisms for fugitive emissions. Differences in nebulizer design had an impact in the amount and type of fugitive emissions emitted.
Through the choice of an appropriate nebulizer, the natural risk can be greatly reduced, and through selection of appropriate mitigation strategies, the risk can be almost eliminated.
A systematic review of nebulizer use highlighted a few different potential mechanisms for fugitive emissions. Differences in nebulizer design had an impact in the amount and type of fugitive emissions emitted.
Through the choice of an appropriate nebulizer, the natural risk can be greatly reduced, and through selection of appropriate mitigation strategies, the risk can be almost eliminated.
Medication delivery can vary significantly depending on the pMDI/spacer system which will have implications on the carbon footprint. In this case, the use of the AeroChamber Plus* Flow-Vu* spacer could potentially reduce the carbon footprint by up to five-fold compared to other spacers.
